*Clinical Endocrinology* (1983) **18**, 651–656

# Author Index to Volume 18


ADRIAN, T.E., see Fink, R.S. *et al.*
ALAGHBAND-ZADEH, J., see Reader, S.J.C. *et al.*
ALBERTI, K.G.M.M., see McCulloch, A.J. *et al.*, also Stubbs, W.A. *et al.*
ALMQVIST, S., see Tegler, L. *et al.*
ANDERSON, D.C., see Dewis, P. *et al.*
ARATAKE, Y., see Endo, Y. *et al.*
ARENA, R., see Barreca, T. *et al.*
ARONIN, N. and KRIEGER, D.T. Plasma immunoreactive β-endorphin is elevated in uraemia, 459
ATKINSON, S., see Hardisty, C.A. *et al.*

BALÁZS, C., see Stenszky, V. *et al.*
BALL, S.G., see Connell, J.M.C. *et al.*
BARNETT, A.H., LIVESEY, J.H., FRIDAY, K., DONALD, R.A. and ESPINER, E.A. Comparison of preoperative and postoperative ACTH concentrations after bilateral adrenalectomy in Cushing's disease, 301
BARRECA, T., ROSSI, B., MAGNANI, G., SARTUCCI, F., ARENA, R. and ROLANDI, E. Nyctohemeral pattern of serum LH, FSH and PRL in patients with myotonic dystrophy, 319
BARRON, J.L., see Millar, R.P. *et al.*
BAXENDALE, P.M., JACOBS, H.S. and JAMES, V.H.T. Plasma and salivary androstenedione and dihydrotestosterone in women with hyperandrogenism, 447
BEAR, J.C., see Stenszky, V. *et al.*
BEARDWELL, C.G., see MacFarlane, I.A. *et al.*
BEARSTALL, G.H., see Connell, J.M.C. *et al.*
BELL, G.M., SAWERS, J.S.A., FORFAR, J.C., DOIG, A. and TOFT, A.D. The effect of minor increments in plasma thyroxine on heart rate and urinary sodium excretion, 511
BENRAAD, T.J., see Wellen, J.J. *et al.*
BESSER, G.M., see Delitala, G. *et al.*, also Morretti, C. *et al.*, also Stubbs, W.A. *et al.*
BJERRE, P., see Lindholm, J. *et al.*
BIRD, D., see Lever, A. *et al.*
BLETHEN, S.L., see Witt, M.F. and Blethen, S.L.
BLOOM, S.R., see Cassar, J. *et al.*, also Fink, R.S. *et al.*
BODDY, K., see McAreavey, D. *et al.*
BOLTON, N.J., see Hammond, G.L. *et al.*
BORDI, C., see Minopoli, M. and Bordi, C.
BRADWELL, A.R., see Fairweather, D.S. *et al.*
BRATUSCH-MARRAIN, P., see Vierhapper, H. *et al.*
BROWN, J.J., see McAreavey, D. *et al.*
BU'LOCK, D., see Dewis, P. *et al.*
BUNTING, E.A., see Connel, J.M.C. *et al.*
BYFIELD, P.G.H. see Lalloz, M.R.A. *et al.*, also Lever, A. *et al.*

CALZOLARI, A., see Moretti, C. *et al.*
CAMANNI, F., see Massara, F. *et al.*
CAPPA, M., see Morretti, C. *et al.*
CASSAR, J., GHATEI, M.A., SARSON, D.L., JOPLIN, G.F., MASHITER, K. and BLOOM, S.R. Enteroglucagon and GIP after oral glucose in patients with prolactinoma and acromegaly, 95
CHANDLER, S., see Fairweather, D.S. *et al.*
CHAPMAN, C., see El Sheikh, M.A.A. *et al.*, also Martin, R.H. *et al.*
CHEN, C.N., see Wheeler, M.J. *et al.*
CHRISTENSEN, N.J., see Krarup, T. *et al.*
CLARK, F., see McCulloch, A.J. *et al.*
CLAUS, M., see Schöneshöfer, M. *et al.*
COHEN, D.L., DIENGDOH, J.V., THOMAS, D.G.T. and HIMSWORTH, R.L. An intracranial metastasis from a PRL secreting pituitary tumour, 259
CONNELL, J.M.C., PADFIELD, P.L., BUNTING, E.A., BALL, S.G., INGLISS, G.S., BEASTALL, G.H., TEASDALE, G.M. and DAVIES, D.L. Inhibition of prolactin secretion by low-dose dopamine infusion in patients with hyperprolactinaemia, 526
COOK, D., see Ratter, S.J. *et al.*
COOPER, D.S., KLIBANSKI, A. and CHESTER RIDGWAY, E. Dopaminergic modulation of TSH and its subunits: *in vivo* and *in vitro* studies, 265
COUZINET, B., see Schaison, G. *et al.*
CRISP, A.H., see Wheeler, M.J. *et al.*
CULLITON, M., see Moore, A. *et al.*
CUMMING, A.M.M., see McAreavey, D. *et al.*
CUNNINGHAM, S., see Moore, A. *et al.*

DALY, J.R., see Reader, S.J.C. *et al.*
DAVIES, D.L. see Connell, J.C.M. *et al.*, also MacFarlane, I.A. *et al.*
DE BISCOP, G., see Deslypere, J.P. *et al.*
DEGROOT, L.J., see Pacini, F. and Degroot, L.J.
DELITALA, G., GROSSMAN, A. and BESSER, G.M. Opiate peptides control growth hormone through a cholinergic mechanism in man, 401
DELITALA, G., see Stubbs, W.A. *et al.*
DESLYPERE, J.P., DE BISCOP, G. and VERMEULEN, A. Seasonal variation of plasma dehydroepiandrosterone sulphate and urinary androgen excretion in post-menopausal women, 25
DEWIS, P., ANDERSON, D.C., BU'LOCK, D.E., EARN-

SHAW, R. and KELLY, W.F. Experience with trilostane in the treatment of Cushing's syndrome, 533
DIENGDOH, J.V., see Cohen, D.L. *et al.*
DOIG, A., see Bell, G.M. *et al.*
DOLFIN, G.C., see Massara, F. *et al.*
DONALD, R.A., WHEELER, M., SÖNKSEN, P.H. and LOWRY, C. Hypogonadotrophic hypogonadism resistant to hCG and responsive to LHRH: report of a case, 385
DONALD, R.A., see Barnett, A.H. *et al.*, also Ferguson, J.K. *et al.*
DRURY, P.L., see Oliver, M.H. *et al.*
DUNKEL, L., see Tapanainen, J. *et al.*
DYKES, P.W., see Fairweather, D.S. *et al.*

EAGLE, M.R., see Prince, R.L. *et al.*
EARNSHAW, R., see Dewis, P. *et al.*
EASTMAN, C.J., see Maberly, G.F. *et al.*
EDWARDS, C.R.W., see Ratter, S.J. *et al.*, also Stubbs, W.A. *et al.*
EDWARDS, O.M., see Wheatley, T. and Edwards, O.M.
EDWARDS, R.H.T., see Khaleeli, A.A. *et al.*
EISMAN, J.A., see Prince, R.L. *et al.*
EL SHEIKH, M.A.A., MOLLEY, B.G., OAKEY, R.E., CHAPMAN, C., HANCOCK, K.W. and GLASS, M.R. LH pulse frequency in relation to positive oestrogen-gonadotrophin feedback in amenorrhoea, 517
EL SHEIKH, M.A.A., see Martin, R.H. *et al.*
ENDO, Y., ARATAKE, Y., YAMAMOTO, I., NAKAGAWA, H., KURIBAYASHI, T. and OHTAKI, S. Peripheral K cells in Graves' disease and Hashimoto's thyroiditis in relation to circulating immune complexes, 187
ESPINER, E.A., see Barnett, A.H. *et al.*, also Ferguson, J.K. *et al.*
ETTA, K.M., see Onuora, C. *et al.*

FABBRI, A., see Morretti, C. *et al.*
FAHLBUSCH, R., see Mashiter, K. *et al.*
FAIRWEATHER, D.S., BRADWELL, A.R., WATSON-JAMES, S.F., DYKES, P.W., CHANDLER, S. and HOFFENBERG, R. Detection of thyroid tumours using radiolabelled anti-thyroglobulin, 563
FARID, N.R. see Stenszky, V. *et al.*
FAWCITT, R., see Kelly, W. *et al.*
FENNER, A., see Schöneshöfer, M. *et al.*
FERGUSON, J.K., DONALD, R.A., WESTON, T.S. and ESPINER, E.A. Skin thickness in patients with acromegaly and Cushing's syndrome and response to treatment, 347.
FILL, H., see Mashiter, K. *et al.*
FINK, R.S., ADRIAN, T.E. MARGOT, D.H. and BLOOM, S.R. Increased plasma pancreatic polypeptide in chronic alcohol abuse, 417
FORFAR, J.C., see Bell, G.M. *et al.*
FRAIOLI, F., see Morretti, C. *et al.*
FRASER, R., see McAreavey, D. *et al.*
FRIDAY, K., see Barnett, A.H. *et al.*
FUJIMAKI, M., see Nadahama, S. *et al.*
FUKUNAGA, M., see Shimatsu, A. *et al.*
FULLER, P.J., PETTIGREW, I.G., PIKE, J.W. and STOCKIGT, J.R. An adrenal adenoma causing virilization of mother and infant, 143
FUNDER, J.W., see Khalid, B.A.K. *et al.*

GAILLARD, R., see Ratter, S.J. *et al.*
GALLIGAN, J., see Holt, G. *et al.*
GHATEI, M.A., see Cassar, J. *et al.*
GILLIES, G., see Ratter, S.J. *et al.*
GILLQUIST, J., see Tegler, L. *et al.*
GLASS, M.R., see El Sheikh, M.A.A. *et al.*
GNESSI, L., see Morretti, C. *et al.*
GOHIL, K., see Khaleeli, A.A. *et al.*
GROSSMAN, A., see Delitala, G. *et al.*, also Morretti, C. *et al.*, also Ratier, S.J. *et al.*
GYLDENSTED, C., see Lindholm, J. *et al.*
GYORKI, S., see Khalid, B.A.K. *et al.*

HAGEN, C., see Lindholm, J. *et al.*
HAGUE, W.M. and HONOUR, J.W. Malignant hypertension in congenital adrenal hyperplasia due to 11$\beta$-hydroxylase deficiency, 505
HALE, A.C., see Ratter, S.J. *et al.*
HANCOCK, K.W., see El Sheikh, M.A.A. *et al.*
HANDELSMAN, D.J. and TURTLE, J.R. Testicular damage after radioactive iodine (I-131) therapy for thyroid cancer, 465
HAMMOND, G.L., LEINONEN, P., BOLTON, N.J. and VIHKO, R. Measurement of sex hormone binding globulin in human amniotic fluid: its relationship to protein and testosterone concentrations, and fetal sex, 377
HANNING, I., see McCulloch, A.J. *et al.*
HARDISTY, C.A., KENDALL-TAYLOR, P., ATKINSON, S., HUMPHRIES, H. and MUNRO, D.S. The assay of Graves' immunoglobulins: a comparison of different methods, 637
HEINE, R., see McCulloch, A.J. *et al.*
HILSTED, J., see Krarup, T. *et al.*
HIMSWORTH, R.L., see Cohen, D.L. *et al.*, also Lalloz, M.R.A. *et al.*, also Lever, R.L. *et al.*
HOFFENBERG, R., see Fairweather, D.S. *et al.*
HOLT, G., GALLIGAN, J., WINSHIP, J., ROESER, P., and MORTIMER, R. Serum thyroglobulin after mantle irradiation for Hodgkin's disease, 605
HOME, P.D., see McCulloch, A.J. *et al.*
HONOUR, J.W., see Hague, W.M. and Honour, J.W.
HOPE, J., see Ratter, S.J. *et al.*
HOW, J., TOPLISS, D.J., STRAKOSCH, C., LEWIS, M., ROW, V.V. and VOLPÉ, R. T lymphocyte sensitization and suppressor T lymphocyte defect in

patients long after treatment for Graves' disease, 61
HSU, L.K.G., see Wheeler, M.J. *et al.*
HUMPHRIES, H., see Hardisty, C.A. *et al.*

IMURA, H., see Shimatsu, A. *et al.*
INGLISS, G.C., see Connell, J.M.C. *et al.*
ISLES, C.G. and JOHNSON, J.K. Phaeochromocytoma and diabetes mellitus: further evidence that $\alpha_2$ receptors inhibit insulin release in man, 37

JACOBS, H.S., see Baxendale, P.M. *et al.*
JAMES, V.H.T., see Baxendale, P.M. *et al.*
JOHNSON, J.K., see Isles, C.G. and Johnson, J.K.
JOHNSTON, D.G., see McCulloch, A.J. *et al.*
JOPLIN, G.F., see Cassar, J. *et al.*
JØRGENSEN, J.V., see Krølner, B. *et al.*

KATAOKA, K., see Kohri, K. *et al.*
KATO, Y. see Shimatsu, A. *et al.*
KAUR, S., see Ramsay, I. *et al.*
KAWABE, H., see Nagahama, S. *et al.*
KEELEY, J. see Kelly, W. *et al.*
KELLY, W., LONGSON, D., SMITHARD, D., FAWCITT, R., WENSLEY, R., NOBLE, J. and KEELEY, J. An evaluation of plasma exchange for Graves' ophthalmopathy, 485
KELLY, W.F., see Dewis, P. *et al.*
KENDALL-TAYLOR, P., see Hardisty, C.A. *et al.*
KESSON, C.M., see Scobie, I.N. *et al.*
KHALEELI, A.A., EDWARDS, R.H.T., GOHIL, K., MCPHAIL, G., RENNIE, M.J., ROUND, J. and ROSS, E.J. Corticosteroid myopathy: a clinical and pathological study, 155
KHALID, B.A.K., GYORKI, S., WARNE, G.L. and FUNDER, J.W. Cystic fibrosis and normal fibroblasts have identical glucocorticoid receptor profiles and induced protein responses, 407
KLAFF, L.J., see Millar, R.P. *et al.*
KLIBANSKI, A., see Cooper, D.S. *et al.*
KLOPPENBORG, P.W.C., see Wellen, J.J. *et al.*
KNIGGE, U., DEJGAARD, A., WOLLESEN, F., INGERSLEV, O., BENNETT, P. and CHRISTIANSEN, P.M. The acute and long term effect of the $H_2$-receptor antagonists cimetidine and ranitidine on the pituitary-gonadal axis in men, 307
KOHRI, K., KATAOKA, K., YACHIKU, S., KURITA, T. and SONODA, T. Changes in cyclic AMP and electolytes after parathyroidectomy in primary hyperparathyroidism, 371
KORSGAARD CHRISTENSEN, L., see Perrild, H. *et al.*
KOZMA, L., see Stenszky, V. *et al.*
KRARUP, T., MADSBAD, S., HILSTED, J., CHRISTENSEN, N.J., SESTOFT, L. and SCHWARTZ, T.W. Response of pancreatic polypeptide to hypoglycaemia in insulin-dependent diabetics with and without residual $\beta$-cell function, 31
KRASSAS, G., see Ramsy, I. *et al.*
KRIEGER, D.G., see Aronin, N. and Krieger, D.T.
KRØLNER, B., JØRGENSEN, J.V. and NIELSEN, S.P. Spinal bone mineral content in myxoedema and thyrotoxicosis. Effects of thyroid hormone(s) and antithyroid treatment, 439
KURIBAYASHI, T., see Endo, Y. *et al.*
KURITA, T., see Kohri, K. *et al.*
KVETNEY, J. Nuclear binding and cellular metabolism of thyroxine in a euthyroid patient with hyperthyroxinaemia, 251

LABROOY, S., see Stubbs, W.A. *et al.*
LALLOZ, M.R.A., BYFIELD, P.G.H. and HIMSWORTH, R.L. Hyperthyroxinaemia: abnormal binding of T4 by an inherited albumin variant, 11
LALLOZ, M.R.A., see Lever, A. *et al.*
LECKIE, B.J., see McAreavey, D. *et al.*
LEINONEN, P., see Hammond, G.L. *et al.*
LEVER, A., BIRD, D., BYFIELD, P.G.H., LALLOZ, M.R.A., WEBSTER, A.D.B. and HIMSWORTH, R.L. Increased serum concentration of T4 binding globulin in patients with hypogammaglobulinaemia, 195
LEVER, A.F., see McAreavey, D. *et al.*
LEVITT, N.S., see Millar, R.P. *et al.*
LEWIS, M., see How, J. *et al.*
LINDHOLM, J., BJERRE, P., RIISHEDE, J., GYLDENSTED, C. and HAGEN, C. Pituitary function in patients with evidence of spontaneous disappearance of a pituitary adenoma, 599
LINDVALL, R., see Tegler, L. *et al.*
LING, N., see Millar, R.P. *et al.*
LIVESEY, J.H., see Barnett, A.H. *et al.*
LONGSON, D., see MacFarlane, I.A. *et al.*, also Kelly, W. *et al.*
LOWRY, C., see Donald, R.A. *et al.*

MABERLY, G.F., EASTMAN, C.J., SMITH, H.C. and WAITE, K. Plasma contamination accounts for thyroid hormone binding in nuclear protein extracts from human mononuclear cells, 241
MACCUISH, A.C., see Scobie, I.N. *et al.*
MACFARLANE, I.A., DAVIES, D., LONGSON, D., SHALET, S.M. and BEARDWELL, C.G. Single daily dose short term carbimazole therapy for hyperthyroid Graves' disease, 557
MACFARLANE, I.A., SHALET, S.M., BEARDWELL, C.G., APPLEGATE, G., ROBINSON, E.L and SUTTON, M.L. External pituitary irradiation as a cause of TRH deficiency in patients with pituitary adenomas, 201
MADSBAD, S., see Krarup, T. *et al.*
MAGEE, F., see Moore, A. *et al.*
MAGNANI, G., SEE BARRECA, T. *et al.*
MAHARAJAN, G., see Onuora, C. *et al.*
MARGOT, D.H., see Fink, R.S. *et al.*

MARTIKAINEN, H., see Tapanainen, J. *et al.*
MARTIN, R.H. The place of PRL in human lactation, 295
MARTIN, R.H., EL SHEIKH, M.A.A. and CHAPMAN, C. Dydrogesterone increases serum lactalbumin concentration in the puerperium, 621
MARTRA, M., see Massara, F. *et al.*
MASHITER, K., VAN NOORDEN, S., FAHLBUSCH, R., FILL, H. and SKRABAL, K. Hyperthyroidism due to a TSH secreting adenoma: case report, treatment and evidence for adenoma TSH by morphological and cell culture studies, 473
MASHITER, K., see Cassar, J. *et al.*
MASSARA, F., CAMANNI, F., MARTRA, M., DOLFIN, G.C., MULLER, E.E. and MOLINATTI, G.M. Reciprocal pattern of the TSH and PRL responses to dopamine receptor blockade in women with physiological or pathological hyperprolactinaemia, 103
MCAREAVEY, D., CUMMING, A.M.M., BODDY, K., BROWN, J.J., FRASER, R., LECKIE, B.J., LEVER, A.F., MORTON, J.J., ROBERTSON, J.I.S. and WILLIAMS, E.D. The renin-angiotensin system and total body sodium and potassium in hypertensive women taking oestrogen-progestagen oral contraceptives, 111
MCCULLOCH, A.J., HOME, P.D., HEINE, R., PONCHNER, M., HANNING, I., JOHNSTON, D.G., CLARK, F. and ALBERTI, K.G.M.M. Insulin sensitivity in hyperthyroidism: measurement by the glucose clamp technique, 327
MCKENNA, T.J., see Moore, A. *et al.*
MCPHAIL, G., see Khaleeli, A.A. *et al.*
MILLAR, R.P., KLAFF, L.J., BARRON, J.L., LEVITT, N.S. and LING, N. Somatostatin-28 and somatostatin-14 suppression of arginine-, insulin-, and TRH-stimulated GH and PRL secretion in man, 277
MINOPOLI, M. and BORDI, C. Changing patterns of sex distribution on familial medullary carcinoma of the thyroid and associated phaeochromocytoma, 645
MISIEWICZ, J.J. see Stubbs, W.A. *et al.*
MOATTI, N., see Schaison, G. *et al.*
MØLHOLM HANSEN, J., see Perrild, H., *et al.*
MOLINATTI, G.M., see Massara, F. *et al.*
MOLLOY, B.G., see El Sheikh, M.A.A. *et al.*
MOORE, A., MAGEE, F., CUNNINGHAM, S., CULLITON, M. and MCKENNA, J.T. Adrenal abnormalities in idiopathic hirsutism, 391
MORTIMER, R., see Holt, G. *et al.*
MORTON, J.J., see McAreavey, D. *et al.*
MORRETTI, C., FABBRI, A., GNESSI, L., CAPPA, M., CALZOLARI, A., FRAIOLO, F., GROSSMAN, A. and BESSER, G.M. Naloxone inhibits exercise induced release of PRL and GH in athletes, 135
MULLER, E.E., see Massara, F. *et al.*
MUNRO, D.S. see Hardisty, C.A. *et al.*

NAGAHAMA, S., FUJIMAKI, M., KWABE, H., NAKAMURA, R., SAITO, I. and SARUTA, T. Effect of metoclopramide on the secretion of aldosterone and other adrenocortical steroids, 287
NAKAI, Y., see Shimatsu, A., *et al.*
NAKAGAWA, H., see Endo, Y. *et al.*
NAKAMURA, R., see Nagahama, S. *et al.*
NIELSEN, S.P., see Krølner, B. *et al.*
NOBLE, J., see Kelly, W. *et al.*
NOWOTNY, P., see Vierhapper, H. *et al.*

OAKEY, R.E., see El Sheikh, M.A.A. *et al.*
OHTAKI, S., see Endo, Y. *et al.*
OLIVER, M.H., DRURY, P.L. and VAN'T HOFF, W. A case of multiple endocrine adenomatosis (Type I) with nesidioblastosis, terminating with an exocrine pancreatic carcinoma, 495
ONUORA, C., MAHARAJAN, G., SINGH, A. and ETTA, K.M. Thyroid status in various degrees of protein-calorie malnutrition in children, 87
OPIE, J.M., see Prince, R.L. *et al.*
OSMOND, S., see Prince, R.L. *et al.*

PACINI, F. and DEGROOT, L.J. Studies of immunoglobulin synthesis in cultures of peripheral T and B lymphocytes: reduced T-suppressor cell activity in Graves' disease, 219
PADFIELD, P.L., see Connell, J.M.C. *et al.*
PANZER, S., see Vierhapper, H. *et al.*
PERHEENTUPA, J., see Tapanainen, J. *et al.*
PERRILD, H., MØLHOLM HANSEN, J., SKOVSTED, L. and KORSGAARD CHRISTENSEN, L. Different effects of propanolol, alprenolol, sotalol, atenolol and metoprolol on serum T3 and serum rT3 in hyperthyroidism, 139
PERTUISET, B., see Schaison, G. *et al.*
PETTIGREW, I.G., see Fuller, P.J. *et al.*
PIKE, J.W., see Fuller, P.J. *et al.*
PONCHNER, M., see McCulloch, A.J. *et al.*
PRINCE, R.L., WARK, J.D., OSMOND, S., OPIE, J.M., EAGLE, M.R. and EISMAN, J.A. A test of 1,25-dihydroxyvitamin $D_3$ secretory capacity in normal subjects for application in metabolic bone diseases, 127

RAMSAY, I., KAUR, S. and KRASSAS, G. Thyrotoxicosis in pregnancy: results of treatment by antithyroid drugs combined with T4, 73
RAMSDEN, D.B., see Sheppard, M.C. and Ramsden, D.B.
RATCLIFFE, J.G., see Scobie, I.N. *et al.*
RATTER, S.J., GILLIES, G., HOPE, J., HALE, A.C., GROSSMAN, A., GAILLARD, R., COOK, D., EDWARDS, C.R.W. and REES, L.H. Pro-opiocor-

tin related peptides in human pituitary and ectopic ACTH secreting tumours, 211
READER, S.J.C., DALY, J.R., ALAGHBAND-ZADEH, J. and ROBERTSON, W.R. Negative feedback effects on ACTH secretion by cortisol in Cushing's disease, 43
RENNIE, M.J., see Khaleeli, A.A. *et al.*
REES, L.H., see Ratter, S.J. *et al.*
RIDGWAY, E.C., see Cooper, D.S. *et al.*
RIISHEDE, J., see Lindholm, J. *et al.*
RIJKEN, J.C.W., see Wellen, J.J. *et al.*
ROBERTSON, J.I.S., see McAreavey, D. *et al.*
ROBERTSON, W.R., see Reader, S.J.C. *et al.*
ROCHLITZ, S., see Stenszky, V. *et al.*
ROESER, P., see Holt, G. *et al.*
ROLANDI, E., see Barreca, T. *et al.*
ROOS, P., see Tegler, L. *et al.*
ROSS, E.J., see Khaleeli, A.A. *et al.*
ROSSI, B., see Barreca, T. *et al.*
ROUND, J., see Khaleeli, A.A. *et al.*
ROW, V.V., see How, J. *et al.*

SAITO, I., see Nagahama, S. *et al.*
SARSON, D.L., see Cassar, J. *et al.*
SARTUCCI, F., see Barreca, T. *et al.*
SARUTA, T., see Nagahama, S. *et al.*
SAWERS, J.S.A., see Bell, G.M. *et al.*
SCHAISON, G., COUZINET, B., MOATTI, N. and PERTUISET, B. Critical study of the growth hormone response to dynamic tests and the insulin growth factor assay in acromegaly after microsurgery, 541
SCHÖNESHÖFER, M., FENNER, A. and CLAUS, M. Suppressive effect of metapyrone on plasma corticotrophin immunoreactivity in normal man, 363
SCHWARTZ, T.W., see Krarup, T. *et al.*
SCOBIE, I.N., KESSON, C.M., RATCLIFFE, J.G. and MACCUISH, A.C. The effects of prolonged bromocriptine administration on PRL secretion, GH and glycaemic control in stable insulin-dependent diabetes mellitus, 179
SESTOFT, L., see Krarup, T. *et al.*
SHALET, S.M., see MacFarlane, I.A. *et al.*
SHEPPARD, M.C. and RAMSDEN, D.B. Thyroid hormones in non-insulin dependent diabetes before and after dietary treatment, 593
SHIMATSU, A., KATO, Y., TANAKA, I., NAKAI, Y., FUKUNAGA, M. and IMURA, H. Plasma calcitonin and ACTH responses to lysine, vasopressin, calcium and pentagastrin in a patient with medullary thyroid carcinoma associated with Cushing's syndrome, 119
SINGH, A., see Onuora, C. *et al.*
SKRABAL, K., see Mashiter, K. *et al.*
SKOVSTED, L., see Perrild, H. *et al.*
SMALS, A.G.H., see Wellen, J.J. *et al.*
SMITH, H.C., see Maberly, G.F. *et al.*
SMITHARD, D., see Kelly, W. *et al.*
SÖNKSEN, P.H., see Donald, R.A. *et al.*
SONODA, T., see Kohri, K. *et al.*
STENSZKY, V., BALÁZS, C., KOZMA, L., ROCHLITZ, S., BEAR, J.C. and FARID, N.R. Identification of subsets of patients with Graves' disease by cluster analysis, 335
STOCKIGT, J.R., see Fuller, P.J. *et al.*
STRAKOSCH, C., see How, J. *et al.*
STUBBS, W.A., DELITALA, G., BESSER, G.M., EDWARDS, C.R.W., LABROOY, S., TAYLOR, R., MISIEWICZ, J.J. and ALBERTI, K.G.M.M. The endocrine and metabolic effects of cimetidine, 167

TANAKA, I., see Shimatsu, A. *et al.*
TAPANAINEN, J., MARTIKAINEN, H., DUNKEL, L., PERHEENTUPA, J. and VIHKO, R. Steroidogenic response to a single injection of hCG in pre- and early pubertal boys, 355
TAYLOR, R., see Stubbs, W.A. *et al.*
TEASDALE, G.M., see Connell, J.C.M. *et al.*
TEGLER, L., GILLQUIST, J., LINDVALL, R., ALMQVIST, S. and ROOS, P. Thyroid hormone secretion rates: response to endogenous and exogenous TSH in men during surgery, 1
THOMAS, D.G.T., see Cohen, D.L. *et al.*
TOFT, A.D., see Bell, G.M. *et al.*
TOPLISS, D.J., see How, J. *et al.*
TURTLE, J.R., see Handelsman, D.J. and Turtle, J.R.

VAN NOORDEN, S., see Mashiter, K. *et al.*
VAN'T HOFF, W., see Oliver, M.H. *et al.*
VERMEULEN, A., see Deslypere, J.P. *et al.*
VIERHAPPER, H., BRATUSCH-MARRAIN, P., WALDHÄUSL, W., NOWOTNY, P. and PANZER, S. Increased secretion of insulin but unchanged secretion of growth hormone in hyperglycaemic type II diabetics treated with acetyl-salicylic acid, 613
VIHKO, R., see Hammond, G.L. *et al.*, also Tapanainen, J. *et al.*
VOLPÉ, R., see How, J. *et al.*

WAITE, K., see Maberly, G.F. *et al.*
WALDHÄUSL, W., see Vierhapper, H. *et al.*
WARK, J.D., see Prince, R.L. *et al.*
WARNE, G.L., see Khalid, B.A.K. *et al.*
WATSON-JAMES, S.F., see Fairweather, D.S. *et al.*
WEBSTER, A.D.B., see Lever, A. *et al.*
WELLEN, J.J., SMALS, A.G.H., RIJKEN, J.C.W., KLOPPENBORG, P.W.C. and BENRAAD, T.J. Testosterone and $\Delta_4$-androstenedione in the saliva of patients with Klinefelter's syndrome, 51
WESTON, T.S., see Ferguson, J.K. *et al.*
WENSLEY, R., see Kelly, W. *et al.*
WHEATLEY, T. and EDWARDS, O.M. Mild hypothyroidism and oedema: evidence for increased capillary permeability to protein, 627

WHEELER, M.J., CRISP, A.H., HSU, L.K.G. and CHEN, C.N. Reproductive hormone changes during weight gain in male anorectics, 423
WHEELER, M., see Donald, R.A. *et al.*
WILLIAMS, E.D., see McAreavey, D. *et al.*
WINSHIP, J., see Holt, G. *et al.*
WITT, M.F. and BLETHEN, S.L. The endocrine evaluation of three children with vasomotor flushes following hypothalamic surgery, 551
YACHIKU, S., see Kohri, K. *et al.*
YAMAMOTO, I., see Endo, Y. *et al.*

ZANOBONI, A., ZECCA, L. and ZANOBONI-MUCIACCIA, W. Failure of inhibition by TRH of L-dopa stimulated GH secretion in patients with alcoholic cirrhosis of the liver, 233
ZANOBONI-MUCIACCIA, W., see Zanoboni, A. *et al.*
ZECCA, L., see Zanoboni, A. *et al.*

*Clinical Endocrinology* (1983) **18,** 657–660

## Subject Index to Volume 18


Acetyl-salicylic acid
  treatment of hyperglycaemic type II diabetics, 613
Acromegaly
  enteroglucagon and GIP in, 95
  skin thickness in, 347
Adrenal
  abnormalities in idiopathic hirsutism, 391
  adenoma causing virilization, 143
  hyperplasia and malignant hypertension, 505
Adrenalectomy
  and ACTH concentrations, 301
Adrenocortical steroids
  effect of metoclopramide on, 287
Alcoholism
  failure of TRH inhibition of L-dopa stimulated GH, 233
  pancreatic polypeptide increased in, 417
Aldosterone
  effect of metoclopramide on, 287
Alprenolol
  effect on T3 and rT3 in hyperthyroidism, 139
Amenorrhoea
  LH pulse frequency and, 517
Androgen
  seasonal urinary excretion in post-menopausal women, 25
Androstenedione
  in hyperandrogenism, 447
  in Klinefelter's syndrome, 51
Anorectics
  reproductive hormone changes during weight gain, 423
Antithyroid drugs
  treatment of thyrotoxicosis, 73
  effect on spinal bone mineral content, 439
Anti-thyroglobulin
  and thyroid tumours, 563
Arginine
  stimulation of GH and PRL suppressed by somatostatin, 277
Assay methods
  Graves' immunoglobulins, 637
Atenolol
  effect on T3 and rT3 in hyperthyroidism, 139

Bromocriptine
  effect on PRL, GH and glycaemic control in diabetes mellitus, 179

Calcitonin
  response to lysine vasopressin, calcium and pentagastrin, 119
Capillary
  increased permeability in hypothyroidism and oedema, 627
Carbimazole
  hyperthyroid Graves' disease, 557
Cholinergic control
  of growth hormone by opiate peptides, 401
Cimetidine
  effect on pituitary-gonadal axis in men, 307
  endocrine and metabolic effects, 167
Cirrhosis of the liver
  failure of TRH inhibition of L-dopa stimulated GH secretion in, 233
Cluster analysis
  of Graves' disease, 335
Contamination
  and thyroid hormone binding in nuclear protein extracts, 241
Corticosteroid myopathy, 155
Corticotrophin
  before and after bilateral adrenalectomy in Cushing's disease, 301
  effect of cortisol in Cushing's disease, 43
Corticotrophin
  effect of metapyrone on, 363
  secreting tumour and pro-opiocortin related peptides, 211
  response to lysine vasopressin, calcium and pentagastrin, 119
Cortisol
  effect on ACTH secretion in Cushing's disease, 43
Cryptorchid boys
  steroidogenic response to hCG, 355
Cushing's disease
  ACTH before and after adrenalectomy, 301
  effect of cortisol on ACTH secretion, 43
Cushing's syndrome
  calcitonin and ACTH responses to lysine vasopressin, calcium and pentagastrin in, 119
  skin thickness in, 347
  trilostane and, 533
Cyclic AMP
  changes after parathyroidectomy in hyperparathyroidism, 371
Cystic fibrosis
  glucocorticoid receptor profiles and induced protein response identical to normal fibroblasts, 407

Dehydroepiandrosterone sulphate
  season variation in post-menopausal women, 25

Diabetes mellitus
and phaeochromocytoma, 37
effect of bromocriptine administration on PRL, GH and glycaemic control, 179
thyroid hormones and dietary treatment, 593
Dietary treatment for diabetes
and thyroid hormones, 593
Dihydrotestosterone
in hyperandrogenism, 447
Dopamine
inhibition of PRL in hyperprolactinaemia, 526
receptor blockade response of TSH and PRL in hyperprolactinaemia, 103
Dydrogesterone
and lactalbumin in the puerperium, 621

Electrolytes
changes after parathyroidectomy in hyperparathyroidism, 371
β-Endorphin
in uraemia, 459
Enteroglucagon
and GIP in prolactinoma and acromegaly, 95

Familial medullary carcinoma
and sex distribution, 645
Fetal sex
and sex hormone binding globulin, 377
Follicle stimulating hormone
in myotonic dystrophy, 319

Gastric inhibitory polypeptide
and enteroglucagon, 95
in patients with prolactinoma and acromegaly, 95
Glucocorticoid receptor profiles
identical in cystic fibrosis and normal fibroblasts, 407
Glucose
enteroglucagon and GIP after, 95
Glucose clamp technique
measurement of insulin in hyperthyroidism, 327
Glycaemic control
effect of bromocriptine on, 179
Graves' disease
carbimazole and, 557
cluster analysis, 335
lymphocytes after treatment for, 61
peripheral K cells in, 187
reduced T-suppressor activity in, 219
Graves' immunoglobulins
assay methods, 637
Graves' ophthalmopathy
plasma exchange for, 485
Growth hormone
acromegaly and, 541
effect of bromocriptine on, 179
insulin growth factor and, 541
naloxone and, 135
opiate peptides and, 401
stimulation by arginine, insulin and TRH suppressed by somatostatin, 277
unchanged in hyperglycaemic type II diabetics treated with acetyl-salicylic acid, 613

Hashimoto's thyroiditis
peripheral K cells in, 179
Heart rate
effect of thyroxine on, 511
Hirsutism
idiopathic and adrenal abnormalities, 391
Hodgkin's disease
thyroglobulin after irradiation for, 605
Human chorionic gonadotrophin
and hypogonadotrophic hypogonadism, 385
steroidogenic response in cryptorchid boys, 355
β-Hydroxylase deficiency
malignant hypertension in congenital adrenal hyperplasia, 505
Hyperandrogenism
androstenedione and dihydrotestosterone, 447
Hyperglycaemic type II diabetics
insulin and GH after acetyl-salicylic acid treatment, 613
Hyperparathyroidism
changes in cAMP and electrolytes after parathyroidectomy, 371
Hyperprolactinaemia
and inhibition of PRL by dopamine, 526
TSH and PRL response to dopamine receptor blockade, 103
Hyperthyroid Graves' disease
carbimazole and, 557
hyperthyroidism
and a TSH secreting pituitary adenoma, 473
T3 and rT3 in, 139
Hyperthyroxinaemia
abnormal binding of T4 in, 11
nuclear binding and cellular metabolism of thyroxine in hyperthyroxinaemia, 251
Hypogammaglobulinaemia
thyroxine binding globulin in, 195
Hypoglycaemia
response of pancreatic polypeptide to, 31
Hypogonadotrophic hypogonadism
resistant to hCG and responsive to LHRH, 385
Hypothalamic surgery
vasomotor flushes following, 551
Hypothyroidism
and oedema: evidence for increased capillary permeability to protein, 627

Idiopathic hirsutism
and adrenal abnormalities, 391

Immunoglobulin
synthesis in lymphocyte cultures, 219
Induced protein response
identical in cystic fibrosis and normal fibroblasts, 407
Insulin
in hyperthyroidism, 327
increased in hyperglycaemic type II diabetics treated with acetyl-salicylic acid, 613
release inhibited by $\alpha_2$ receptors, 37
stimulation of GH and PRL suppressed by somatostatin, 277
Intracranial metastasis
from a PRL secreting tumour, 259
Irradiation
of pituitary, 201

Klinefelter's syndrome
testosterone and $\Delta_4$-androstenedione in saliva, 51

Lactalbumin
and dydrogesterone in the puerperium, 621
Lactation
and PRL, 295
L-Dopa
and GH secretion in alcoholism, 233
Liver cirrhosis
failure of TRH inhibition of L-dopa stimulated GH secretion in, 233
Luteinizing hormone
in myotonic dystrophy, 319
Luteinizing hormone releasing hormone
and hypogonadotrophic hypogonadism, 385
and positive oestrogen-gonadotrophin feedback in amenorrhoea, 517
Lymphocytes
after treatment for Graves' disease, 61
culture and immunoglobulin synthesis, 219
sensitization after treatment for Graves' disease, 61

Malignant hypertension
and congenital adrenal hyperplasia due to 11$\beta$-hydroxylase deficiency, 505
Malnutrition
and thyroid in children, 87
Medullary thyroid carcinoma
calcitonin and ACTH responses to lysine vasopressin, calcium and pentagastrin in, 119
Metapyrone
effect on corticotrophin immunoreactivity, 363
Metastasis
from a PRL secreting tumour, 259
Metoclopramide
effect on aldosterone and adrenocortical steroids, 287
Metroprolol
effect on T3 and rT3 in hyperthyroidism, 139
Mononuclear cells
plasma contamination and thyroid hormone binding in nuclear protein extracts, 241
Multiple endocrine adenomatosis
with nesidioblastosis and exocrine pancreatic carcinoma, 495
Myotonic dystrophy
LH, FSH and PRL in, 319
Myxoedema
spinal bone mineral content in, 439

Naloxone
PRL and GH in athlete's and, 135
Nesidioblastosis
multiple endocrine adenomatosis and, 495
Nuclear protein extracts
plasma contamination and thyroid hormone binding, 241

Oedema
evidence for increased capillary permeability to proteins, 627
Opiate peptides
and growth hormone, 401

Pancreatic polypeptide
and $\beta$-cell function, 31
in alcoholism, 417
in insulin-dependent diabetics, 31
response to hypoglycaemia, 31
Parathyroidectomy
changes in cAMP and electrolytes, 371
Phaeochromocytoma
and diabetes mellitus, 37
Pituitary adenoma
secreting thyrotrophin and hyperthyroidism, 473
spontaneous disappearance, 599
Pituitary-gonadal axis
effect of cimetidine and ranitidine, 307
Pituitary irradiation,
and TRH deficiency, 201
Pituitary tumour
and pro-opiocortin related peptides, 211
Plasma
contamination and thyroid hormone binding, 241
exchange for Graves' ophthalmopathy, 485
Potassium
and renin-angiotensin in hypertensive women on oral contraceptives, 111
Pregnancy
thyrotoxicosis in, 73
Prolactin
effect of bromocriptine on, 179
from a pituitary tumour and intracranial metastasis, 259

inhibition by low dose dopamine in hyperprolactinaemia, 526
in lactation, 295
in myotonic dystrophy, 319
naloxone and, 135
response to dopamine receptor blockade in hyperprolactinaemia, 103
stimulated by arginine, insulin and TRH suppressed by somatostatin, 277
Prolactinoma
enteroglucagon and GIP in, 95
Pro-opiocortin related peptides
in pituitary and ACTH secreting tumours, 211
Propanolol
effect on T3 and rT3 in hyperthyroidism, 139
Protein-calorie malnutrition
and thyroid in children, 87
Puerperium
dydrogesterone increases lactalbumin in, 621

Radio-active idodine therapy
and testicular damage, 465
Radio-labelled anti-thyroglobulin
and thyroid tumours, 563
Ranitidine
effect on pituitary-gonadal axis in men, 307
Renin-angiotensin
and sodium and potassium in hypertensive women on oral contraceptives, 111
Reproductive hormones
in male anorectics, 423

Saliva
testosterone and $\Delta_4$-androstenedione in, 51
Sex distribution
in familial medullary carcinoma of the thyroid, 645
Sex hormone binding globulin
in amniotic fluid, 377
Skin thickness
in acromegaly and Cushing's syndrome, 347
Sodium
and renin-antiotensin in hypertensive women on oral contraceptives, 111
effect of thyroxine on excretion, 511
Somatostatin
suppression of arginine, insulin and TRH stimulated GH and PRL, 277
Sotalol
effect on T3 and rT3 in hyperthyroidism, 139
Spontaneous disappearance
of pituitary adenoma, 599
Steroidogenic response
to hCG in cryptorchid boys, 355
Suppressor T lymphocyte
after treatment for Graves' disease, 61

Testicular damage
after I-131 therapy, 465
Testosterone
in Klinefelter's syndrome, 51
sex hormone binding globulin and, 377
Thyroid
detection of tumours by labelled anti-thyroglobulin, 563
familial medullary carcinoma and phaeochromocytoma, 645
malnutrition and, 87
testicular damage after radio-active iodine therapy, 465
Thyroid hormones
and dietary treatment for diabetes, 593
effect of TSH on, 1
effect on spinal bone mineral content, 439
Thyroglobulin
after mantle irradiation for Hodgkin's disease, 605
Thyrotoxicosis
in pregnancy, 73
spinal bone mineral content in, 439
treatment by antithyroid drugs and thyroxine, 73
Thyrotrophin
dopaminergic modulation, 265
from a pituitary adenoma, 473
response to domamine receptor blockade in hyperprolactinaemia, 103
Thyrotrophin releasing hormone
and L-dopa stimulated GH secretion in alcoholism, 233
and pituitary irradiation, 201
stimulation of GH and PRL suppressed by somatostatin, 277
Thyroxine
and antithyroid drugs, 73
binding globulin increase in hypogammaglobulinaemia, 195
effect on heart-rate and urinary sodium, 511
in hyperthyroxinaemia, 11
nuclear binding and cellular metabolism in hyperthyroxinaemia, 251
thyrotoxicosis and, 73
Triiodothyronine
propanolol, alprenolol, sotalol, atenolol and metoprolol and, 139
Trilostane
Cushing's syndrome and, 533

Uraemia
$\beta$-endorphin in, 459

Vasomotor flushes
following hypothalamic surgery, 551
Virilization
by an adrenal adenoma, 143
Vitamin D
metabolic bone disease and, 127

Weight gain
reproductive hormones in male anorectics and, 423